title: Hepatitis B virus reactivation in a juvenile rheumatoid arthritis patient under treatment and its successful management: a complicated case.
abstract: Juvenile rheumatoid arthritis is a common chronic inflammatory disease in the childhood and it can differentiate rarely into spondiloarthropaties. It is one of the important causes of chronic pain and disability. Some of the drugs used for the treatment have immunosupressive activity. One of the serious side-effects of immunosupressive treatment is activation of opportunistic pathogens. Hepatitis B virus (HBV) is one of these pathogens, and the rate of carriers in the population is considerably high. It can cause liver damage and death if reactivated. Thus, the management of oppotunistic pathogens becomes a complex issue when treating rheumatic diseases with immunosupressive drugs. In this case report, we present a juvenile rheumatoid arthritis patient whose liver enzymes raised while he was under treatment and afterwards HBV reactivation was determined as the cause. When reactivation was detected, we started controlled antiviral therapy. We achieved successful clinical and laboratory results after adding biological agents to the treatment. Careful evaluation of the patients who have indication for immunosuppressive agents and regular follow-up in case of infection may be protective from severe morbidity and/or mortality.
authors.affiliation: Department of Physical Medicine and Rehabilitation, Gulhane Military Medical Academy, Haydarpasa Training Hospital, Istanbul, Turkey. durmusoguz@gmail.com
authors.forename: Oguz
authors.initials: O
authors.lastname: Durmus
authors.forename: Levent
authors.initials: L
authors.lastname: Tekin
authors.forename: Alparslan Bayram
authors.initials: AB
authors.lastname: Carli
authors.forename: Engin
authors.initials: E
authors.lastname: Cakar
authors.forename: Ali
authors.initials: A
authors.lastname: Acar
authors.forename: Asim
authors.initials: A
authors.lastname: Ulcay
authors.forename: Umit
authors.initials: U
authors.lastname: Dincer
authors.forename: Mehmet Zeki
authors.initials: MZ
authors.lastname: Kiralp
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D001171:Arthritis, Juvenile / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D015415:Biomarkers / Q000097:blood; D057915:Drug Substitution; D000068800:Etanercept; D006147:Guanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006509:Hepatitis B / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D006515:Hepatitis B virus / Q000187:drug effects* / Q000276:immunology / Q000472:pathogenicity; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D008279:Magnetic Resonance Imaging; D008297:Male; D009894:Opportunistic Infections / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome; D014775:Virus Activation / Q000187:drug effects*; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; D015415:Biomarkers; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; C413685:entecavir; D006147:Guanine; D000068800:Etanercept